Sildenafil Vs. Tadalafil for The Treatment of Benign Prostatic Hyperplasia: A Single-arm Self-controlled Clinical Trial
Purpose: To compare the efficacy and adverse events of sildenafil monotherapy for benign prostatic hyperplasia (BPH) with its FDA-approved counterpart, tadalafil.
Materials and methods: In this single-arm self-controlled clinical trial, 33 patients were enrolled. All patients underwent a 6-week treatment with sildenafil, followed by a 4-week washout period and finally a 6-week treatment with tadalafil. Patients were examined on each appointment and post-void residual (PVR) urine, International Prostate Symptom Score (IPSS) and Quality of life index (IPSS-QoL index) were recorded subsequently. Efficacy of each drug regimen was then evaluated by comparing these outcome parameters.
Conclusion: Considering the significantly better improvement of PVR and IPSS-Qol index with sildenafil, this drug can be nominated as a suitable alternative for tadalafil as a BPH treatment, especially in younger patients who don’t have any contraindications.
Similar articles
Singh DV, Mete UK, Mandal AK, Singh SK. Singh DV, et al. J Sex Med. 2014 Jan;11(1):187-96. doi: 10.1111/jsm.12357. Epub 2013 Oct 25. J Sex Med. 2014. PMID: 24165272 Clinical Trial.
Porst H, Roehrborn CG, Secrest RJ, Esler A, Viktrup L. Porst H, et al. J Sex Med. 2013 Aug;10(8):2044-52. doi: 10.1111/jsm.12212. Epub 2013 Jun 19. J Sex Med. 2013. PMID: 23782459 Clinical Trial.
Brock G, Broderick G, Roehrborn CG, Xu L, Wong D, Viktrup L. Brock G, et al. BJU Int. 2013 Nov;112(7):990-7. doi: 10.1111/bju.12251. Epub 2013 Aug 13. BJU Int. 2013. PMID: 23937669 Clinical Trial.
Hatzimouratidis K. Hatzimouratidis K. Ther Adv Urol. 2014 Aug;6(4):135-47. doi: 10.1177/1756287214531639. Ther Adv Urol. 2014. PMID: 25083163 Free PMC article. Review.
Carson CC, Rosenberg M, Kissel J, Wong DG. Carson CC, et al. Int J Clin Pract. 2014 Jan;68(1):94-103. doi: 10.1111/ijcp.12305. Int J Clin Pract. 2014. PMID: 24341303 Review.
